BioNTech has acquired a manufacturing facility from Novartis, which will also serve as its Asia-Pacific regional headquarters. The facility will be the first in Singapore dedicated to the production of mRNA products. BioNTech did not reveal the financial details of the acquisition.
The plant will be fully operational by late 2023 and will have the capacity to produce several hundred million doses of mRNA-based vaccines annually, BioNTech said. The company plans to employ more than 100 there by 2024 and is already recruiting for jobs in engineering, operations, quality control, finance, human resources and supply chain management.
The site is in the Tuas Biomedical Park, the epicentre of biopharma activity in Singapore.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy